Diabetic hearts and biguanides.
D000818:Animals; D001645:Biguanides / Q000009:adverse effects* / Q000627:therapeutic use; D002170:Canada; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality; D002986:Clinical Trials as Topic; D000242:Cyclic AMP / Q000378:metabolism; D003920:Diabetes Mellitus / Q000178:diet therapy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008687:Metformin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D010629:Phenformin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D010919:Placebos; D011446:Prospective Studies; D012189:Retrospective Studies
D001645:Biguanides; D010919:Placebos; D008687:Metformin; D010629:Phenformin; D000242:Cyclic AMP